The role of dupilumab in the treatment of eosinophilic esophagitis

References

• Mansoor E, Cooper GS. The 2010–2015 prevalence of eosinophilic esophagitis in the USA: a population-based study. Dig Dis Sci. 2016;61(10):2928–2934. doi:10.1007/s10620-016-4204-4
   PubMed Web of Science ®Google Scholar
• Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annual Rev Pathology: Mechanisms Dis. 2016;11(1):365–393. doi:10.1146/annurev-pathol-012615-044241
   PubMedGoogle Scholar
• Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–32.e3. doi:10.1053/j.gastro.2017.06.067
   PubMed Web of Science ®Google Scholar
• Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–1648. doi:10.1053/j.gastro.2014.02.006
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22 e1. doi:10.1016/j.cgh.2015.07.041
   PubMed Web of Science ®Google Scholar
• Cotton CC, Eluri S, Wolf WA, et al. Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression. Dig Dis Sci. 2017;62(9):2408–2420. doi:10.1007/s10620-017-4642-7
   PubMed Web of Science ®Google Scholar
• Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672–85 e5. doi:10.1053/j.gastro.2020.07.039
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Katzka DA, et al. Long-term treatment of eosinophilic esophagitis with budesonide oral suspension. Clin Gastroenterol Hepatol. 2022;20(7):1488–1498.e11. doi:10.1016/j.cgh.2021.06.020
   PubMed Web of Science ®Google Scholar
• O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333–345. doi:10.1053/j.gastro.2017.06.065
   PubMed Web of Science ®Google Scholar
• Blanchard C. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–547. doi:10.1172/jci26679
   PubMed Web of Science ®Google Scholar
• Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007;120(6):1292–1300. doi:10.1016/j.jaci.2007.10.024
   PubMed Web of Science ®Google Scholar
• Li Z, Radin A, Li M, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev. 2020;9(6):742–755. doi:10.1002/cpdd.798
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5–14. doi:10.1111/cea.13491
   PubMed Web of Science ®Google Scholar
• Regeneron. DUPIXENT full prescribing information. 2024. https://www.regeneron.com/downloads/dupixent_fpi.pdf
   Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–22.e10. doi:10.1053/j.gastro.2019.09.042
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317–2330. doi:10.1056/nejmoa2205982
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990–1004. doi:10.1016/S2468-1253(23)00204-2
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ, Dellon E, Hirano I, et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 2024;73(3):398–406. doi:10.1136/gutjnl-2023-330220
   PubMed Web of Science ®Google Scholar
• Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024;390(24):2239–2251. doi:10.1056/NEJMoa2312282
   PubMed Web of Science ®Google Scholar
• Lee CJ, Dellon ES. Real-world efficacy of dupilumab in severe, treatment-refractory and fibrostenotic patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2024 .;22(2):252–258. doi:10.1016/j.cgh.2023.08.015
   PubMed Web of Science ®Google Scholar
• Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589–593. doi:10.1016/j.anai.2022.01.019
   PubMed Web of Science ®Google Scholar
• Syverson EP, Rubinstein E. Real world experience with dupilumab in eosinophilic esophagitis in children and young adults at a tertiary care pediatric medical center. JPGN Rep. 2022;3(2):e180. doi:10.1097/PG9.0000000000000180
   PubMedGoogle Scholar
• Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory pediatric fibrostenotic eosinophilic esophagitis treated with dupilumab. ACG Case Rep J. 2022;9(11):e00887. doi:10.14309/crj.0000000000000887
   PubMed Web of Science ®Google Scholar
• Aceves SS, Dellon ES, Greenhawt M, et al. Clinical guidance for the use of dupilumab in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023;130(3):371–378. doi:10.1016/j.anai.2022.12.014
   PubMed Web of Science ®Google Scholar
• Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147. doi:10.1016/j.jaad.2020.08.051
   PubMed Web of Science ®Google Scholar
• Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393–408. doi:10.1007/s40257-022-00685-0
   PubMed Web of Science ®Google Scholar
• Lin T-Y, Wang C-Y, Wang F-Y, et al. Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials. Pharmaceutics. 2023;15(4):1031. doi:10.3390/pharmaceutics15041031
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/nejmoa1804092
   PubMed Web of Science ®Google Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Therapy. 2018;35(5):737–748. doi:10.1007/s12325-018-0702-4
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/nejmoa1804093
   PubMed Web of Science ®Google Scholar
• Owji S, Ungar B, Dubin DP, et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol: In Practice. 2023;11(5):1548–1551. doi:10.1016/j.jaip.2022.12.018
   PubMed Web of Science ®Google Scholar
• Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–199. doi:10.1016/j.jaad.2020.03.050
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi:10.1016/j.jaad.2019.07.074
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respiratory Med. 2022;10(1):11–25. doi:10.1016/S2213-2600(21)00322-2
   PubMed Web of Science ®Google Scholar
• Le Floc'H A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.14151
   PubMed Web of Science ®Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi:10.1016/S0140-6736(22)01539-2
   PubMed Web of Science ®Google Scholar
• K-FRDGKJDWJHB NL. Safety profile of dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). Eur Rev Med Pharmacol Sci. 2021;25:5448–5451.
   PubMed Web of Science ®Google Scholar